美国HIV感染者启动现代抗逆转录病毒方案后高血压风险:五项临床试验血压数据汇总分析
该研究汇总美国五项三期随机试验中2411名初治HIV感染者的血压数据,比较INSTI/TAF、INSTI/非TAF与NNRTI/非TAF方案的高血压风险。结果显示第96周高血压风险及发生时间在各方案间无显著差异。
要点
- 近半数初治HIV感染者在基线时已存在≥1级高血压。
- 第96周时,INSTI/TAF、INSTI/非TAF与NNRTI/非TAF方案间高血压风险无显著差异。
- 各治疗组间血压升高比值比及新发复合高血压时间均无显著差异。
核心结论
- INSTI/TAF、INSTI/非TAF与NNRTI/非TAF方案的高血压风险无显著差异。
研究设计与样本
- 事后汇总分析,纳入美国五项三期随机试验中2411名初治HIV感染者,分别接受NNRTI/非TAF(528例)、INSTI/非TAF(749例)和INSTI/TAF(1134例)方案。
主要发现
- 基线时近半数参与者存在≥1级高血压。
- 第96周NNRTI/非TAF对比INSTI/非TAF的≥1级和≥2级高血压调整风险比分别为1.06(95%CI 0.99–1.13)和1.12(95%CI 0.98–1.27)。
- 第96周NNRTI/非TAF对比INSTI/TAF的≥1级和≥2级高血压调整风险比分别为1.01(95%CI 0.95–1.08)和1.02(95%CI 0.91–1.17)。
- INSTI/非TAF和INSTI/TAF对比NNRTI/非TAF的新发复合高血压风险比分别为0.88(约95%CI 0.66–1.17)和0.98(约95%CI 0.75–1.28)。
关键数值与推荐
- 高血压定义采用美国心脏病学会/美国心脏协会标准。
- 血压比值条件比值比通过比例优势混合效应回归评估至ART启动后108周。
- 新发高血压时间通过Cox比例风险回归建模至96周。
临床怎么用
- 临床选择INSTI/TAF、INSTI/非TAF或NNRTI/非TAF方案时,高血压风险差异不显著。
- 初治HIV感染者中高血压普遍存在,应重视基线及随访血压监测。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with HIV have a greater risk of cardiovascular disease than the general population. Current literature suggests that some ARTs may exacerbate this risk. OBJECTIVES: To estimate the risk of hypertension in treatment-naïve people with HIV receiving integrase strand transfer inhibitor (INSTI)/tenofovir alafenamide (TAF) or INSTI/non-TAF versus NNRTI/non-TAF regimens. METHODS: Post hoc pooled analysis evaluating data from US participants in five Phase 3 randomized studies. Adjusted prevalence of Stage 1 and 2 hypertension (American College of Cardiology/American Heart Association criteria) and conditional odds of higher blood pressure ratios were estimated using proportional odds mixed-effect regression through 108 weeks after ART initiation. Time to incident hypertension through 96 weeks was modelled using Cox proportional-hazards regression. RESULTS: In total, 2411 participants were included (528, 749 and 1134 received NNRTI/non-TAF, INSTI/non-TAF and INSTI/TAF regimens, respectively). Nearly half of participants had hypertension (Stage ≥1) at baseline. The Week 96 adjusted estimates of risk of hypertension (95% CI) were 1.06 (0.99, 1.13) and 1.12 (0.98, 1.27) for Stages ≥1 and ≥2 hypertension, respectively, for NNRTI/non-TAF versus INSTI/non-TAF, and 1.01 (0.95, 1.08) and 1.02 (0.91, 1.17) for Stages ≥1 and ≥2 hypertension, respectively, for NNRTI/non-TAF versus INSTI/TAF. There were no significant differences in conditional odds of high blood pressure between treatment groups. No significant differences were identified in time to incident composite hypertension for INSTI/non-TAF and INSTI/TAF versus NNRTI/non-TAF regimens; estimated hazard ratios (approximate 95% CI) were 0.88 (0.66, 1.17) and 0.98 (0.75, 1.28), respectively. CONCLUSIONS: Results suggest the risk of hypertension is not significantly different across INSTI/TAF, INSTI/non-TAF and NNRTI/non-TAF regimens.
引用
- Hsue PY, Waters L, Orkin C, et al. Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials. J Antimicrob Chemother. 2026. PMID: 41684244. doi:10.1093/jac/dkag005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。